Understanding the in vivo Uptake Kinetics of a Phosphatidylethanolamine-binding Agent \u3csup\u3e99m\u3c/sup\u3eTc-Duramycin by Audi, Said H. et al.
Marquette University
e-Publications@Marquette
Biomedical Engineering Faculty Research and
Publications Biomedical Engineering, Department of
8-1-2012










Medical College of Wisconsin
Wei Fang
Cardiovascular Research Institute - Fuwai Hospital
See next page for additional authors
Accepted version. Nuclear Medicine and Biology, Vol. 39, No. 6 (August 2012): 821-825. DOI. ©
2012 Elsevier. Used with permission.
NOTICE: this is the author’s version of a work that was accepted for publication in Nuclear
Medicine and Biology. Changes resulting from the publishing process, such as peer review, editing,
corrections, structural formatting, and other quality control mechanisms may not be reflected in this
document. Changes may have been made to this work since it was submitted for publication. A
definitive version was subsequently published in Nuclear Medicine and Biology, VOL 39, ISSUE 6,
August 2012, DOI.
Authors
Said H. Audi, Zhixin Li, Joseph Capacete, Yu Liu, Wei Fang, Laura G. Shu, and Ming Zhao
This article is available at e-Publications@Marquette: https://epublications.marquette.edu/bioengin_fac/251
NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be 
accessed by following the link in the citation at the bottom of the page. 
Nuclear Medicine and Biology, Vol. 39, No. 6 (August 2012): pg. 821-825. DOI. This article is © Elsevier and permission has 
been granted for this version to appear in e-Publications@Marquette. Elsevier does not grant permission for this article 





Understanding the in vivo uptake 




Said Audi                                                       
Department of Biomedical Engineering, Marquette University 
Milwaukee, WI                                                               
Zablocki VA Medical Center                                                  
Milwaukee, WI                                                                      
Division of Pulmonary and Critical Care Medicine, Medical College 
of Wisconsin                                                                       
Milwaukee, WI 
 
Zhixin Li                                                             
Department of Biophysics, Medical College of Wisconsin 
Milwaukee, WI 
Joseph Capacete                                     
Department of Biomedical Engineering, Marquette University 
Milwaukee, WI                                                                
Yu Liu                                                                
Department of Biophysics, Medical College of Wisconsin 
Milwaukee, WI 
NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be 
accessed by following the link in the citation at the bottom of the page. 
Nuclear Medicine and Biology, Vol. 39, No. 6 (August 2012): pg. 821-825. DOI. This article is © Elsevier and permission has 
been granted for this version to appear in e-Publications@Marquette. Elsevier does not grant permission for this article 
to be further copied/distributed or hosted elsewhere without the express permission from Elsevier. 
2 
 
Wei Fang                                                           
Cardiovascular Research Institute,                                             
Fuwai Hospital, Beijing, China 
Laura G. Shu                                                    
Department of Biophysics, Medical College of Wisconsin 
Milwaukee, WI 
Ming Zhao                                                        
Department of Biophysics, Medical College of Wisconsin 
Milwaukee, WI                                                                       
Feinberg Cardiovascular Research Institute, Department of 





99mTc-Duramycin is a peptide-based molecular probe that binds 
specifically to phosphatidylethanolamine (PE). The goal was to characterize 
the kinetics of molecular interactions between 99mTc-Duramycin and the target 
tissue. 
Methods 
High level of accessible PE is induced in cardiac tissues by myocardial 
ischemia (30 min) and reperfusion (120 min) in Sprague Dawley rats. Target 
binding and biodistribution of 99mTc-duramycin was captured using SPECT/CT. 
To quantify the binding kinetics, the presence of radioactivity in ischemic 
versus normal cardiac tissues was measured by gamma counting at 3, 10, 20, 
60 and 180 min after injection. A partially inactivated form of 99mTc-
Duramycin was analyzed in the same fashion. A compartment model was 
developed to quantify the uptake kinetics of 99mTc-Duramycin in normal and 
ischemic myocardial tissue. 
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99mTc-duramycin binds avidly to the damaged tissue with a high 
target-to-background radio. Compartment modeling shows that accessibility 
of binding sites in myocardial tissue to 99mTc-Duramycin is not a limiting 
factor and the rate constant of target binding in the target tissue is at 2.2 
ml/nmol/min/g. The number of available binding sites for 99mTc-Duramycin in 
ischemic myocardium was estimated at 0.14 nmol/g. Covalent modification of 
D15 resulted in a 9 fold reduction in binding affinity. 
Conclusion 
99mTc-Duramycin accumulates avidly in target tissues in a PE-
dependent fashion. Model results reflect an efficient uptake mechanism, 
consistent with the low molecular weight of the radiopharmaceutical and the 
relatively high density of available binding sites. These data help better define 
the imaging utilities of 99mTc-Duramycin as a novel PE-binding agent. 
 Keywords: 99mTc-Duramycin, phosphatidylethanolamine, imaging agent. 
INTRODUCTION 
The asymmetrical distribution of phospholipids in cellular 
membranes is of fundamental importance [1,2]. The status of this 
asymmetry has been increasingly recognized as a molecular marker 
for normality and diseases. 
A number of imaging agents have been described in pursuit of 
targeted imaging capabilities for membrane phospholipids. Annexin V, 
the C2A domain of Synaptotagmin I, and the C2 domain of Lactadherin 
are examples of protein-based phosphatidylserine (PS)-binding 
imaging agents [3–5]. Structural features of these agents can be 
generalized as including 1) a binding site designed to accommodate 
the head group of a target phospholipid, and 2) exposed hydrophobic 
side chains at the vicinity of the binding site for interacting with the 
core of the phospholipid bilayer. The first feature enables the 
recognition of phospholipid head groups, while the second provides an 
anchoring mechanism that drives toward membrane binding. 
Duramycin, which is a lantibiotic peptide, also meets the 
structural criteria for targeting phospholipid membranes, but it binds 
specifically to phosphatidylethanolamine (PE) [6]. Apart from 
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apoptosis, emerging evidence indicates that the dynamics of 
membrane PE is involved in a number of biological functions, including 
cytokinesis and possibly hemostasis [7,8]. Thus, the unique binding 
activity of Duramycin adds to the repertoire of membrane-binding 
agents by enabling a new perspective in investigating the fundamental 
biology of membrane phospholipid distribution. Initial studies on 99mTc-
labeled Duramycin indicate that the agent has good uptake in target 
tissues with rapid renal clearance and a low general background in 
vivo [9]. These properties are consistent with the structural features of 
Duramycin. More specifically, Duramycin is one of the smallest 
possible polypeptide (19 amino acids) that has a defined 3-
dimensional binding structure [6,10]. The peptide is extensively cross-
linked by intramolecular covalent bridges, thus exhibiting relatively 
high in vivo stability. The agent has binding activities comparable to 
large proteins, yet with peptide-like pharmacokinetics. The 
combination of these factors makes Duramycin an attractive candidate 
as an imaging agent for studying phospholipid distribution in the living 
system. 
In light of these initial findings, the objective of the current 
study was to understand how 99mTc-Duramycin behaves in the target 
tissue, by quantifying the kinetics of interactions between 99mTc-
Duramycin and its molecular targets in vivo. We hypothesize that the 
combination of high target density and fast probe diffusion in tissue 
will lead to more efficient uptake, thus superior imaging properties. 
The in vivo experiment will be carried using a rat model of 
myocardial ischemia and reperfusion. It has been demonstrated that 
both PE and PS are externalized in dead and dying mammalian cells 
[11]. Additionally, extensive pathological data have documented that 
prolonged ischemia followed by reperfusion causes destabilization of 
sarcolemmal structure. Severe ischemic insult eventually leads to 
compromised phospholipid membrane integrity, rendering high levels 
of phosphatidylethanolamine accessible to extracellular agents [12–
14]. The advantages of using this animal model include a relatively 
defined perfusion profile, high target density in the ischemically 
damaged myocardium versus a low background in the viable 
myocardium. The quantitative dynamic data acquired using this 
system, in turn, will help better define the utilities of 99mTc-Duramycin 
as a novel radiopharmaceutical. Importantly, this type of data will be 
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instrumental in gauging the incremental values of an imaging agent 
compared with past and future generation agents for similar purposes. 
MATERIALS AND METHODS 
Radiolabeling of Duramycin 
Duramycin and its partially inactivated form, DuramycinI, were 
covalently modified with HYNIC. The molecular weight of the HYNIC-
modified Duramycin was confirmed using Matrix-assisted laser 
desorption/ionization (MALDI) mass spectrometry. The 
radiopharmaceutical was prepared using a single-step kit formulation. 
The partially inactivated form of 99mTc-Duramycin was prepared in the 
same fashion. Quality control steps, including stability tests, were 
carried out as described before [11]. The radiopharmaceutical dose 
consistently has a radiochemical purity at 95% or greater, and is 
stable without significant presence of dissociated radioactivity. 
Rat Model of Myocardial Ischemia and Reperfusion 
The animal protocol was approved by the Institutional Animal 
Care and Use Committee under the NIH guideline. Male Sprague-
Dawley rats were anesthetized with sodium pentobarbital (50 mg/kg) 
intraperitoneally. After tracheal intubation, respiration was maintained 
using a rodent ventilator. An incision was made between the 4th 
intercostal space to expose the heart. After opening the pericardium, 
the proximal left anterior descending coronary artery (LAD) was 
occluded for 30 minutes using a 6.0 suture at about 1 mm below the 
left atrial appendage. For sham operation, the suture was passed 
underneath the LAD without ligation. The presence of acute 
ischemia/reperfusion was confirmed by the pale appearance in the 
area-at-risk region and changes in ECG profiles. After reperfusion the 
chest wall was closed and ventilation was maintained until the rat 
could regain spontaneous respiration. The loose suture was left in 
place for area-at-risk staining. 
SPECT studies 
Static SPECT data were acquired at 40 min after radiotracer 
injection (37 MBq, i.v.) on a Triumph microSPECT/microCT scanner 
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(GE Healthcare, Waukesha, WI) equipped with a quad-detector SPECT 
system. The imaging parameters include multi-pinhole collimators for 
rat, 1.0 mm spatial resolution, 1100 counts per MBq sensitivity, 15% 
energy window centering at 140 keV, 50 × 50 mm trans-axial field of 
view, 170 mm axial field of view, 72 projections at 10 seconds each. 
SPECT acquisition was followed by CT, using the same field of view. 
The imaging data were reconstructed using the inbuilt software. 
Spatial and Temporal uptake of 99mTc-Duramycin and 
its partially inactivated form in the area-at-risk 
To investigate the temporal uptake kinetics of 99mTc-Duramycin 
in the area-at-risk, 20 rats were enrolled to simulate acute myocardial 
infarction with 30 min coronary occlusion as described above. At 2 hr 
after reperfusion the radiotracer was injected intravenously (0.1 mCi). 
One group of 4 rats was sacrificed for measurements at each of the 
following time points: 3, 10, 20, 60 and 180 min after injection. 
Immediately before sacrifice, a second thoracotomy was performed to 
expose the heart. The LAD was re-occluded at the same location by 
tightening the suture in place. Two mls of Evans Blue dye (2% w/v in 
PBS, pH 7.4) was infused into the tail vein. Area-at-risk was delineated 
by an absence of blue dye uptake, while the normally perfused 
myocardium is stained dark blue. The heart was quickly excised, and 
the dissected tissues were separately weighed and collected in sample 
tubes for gamma counting as follows: normal (blue), ischemic infarct 
(unstained). Three aliquots of 99mTc-Duramycin solution were taken at 
5 ml each and were measured for radioactivity as standards for the 
calculation of total injected dosage (ID). The radioactivity uptake of 
99mTc-Duramycin at each time point after injection was presented as 
percentage of injected dosage per gram (%ID/g) with standard 
deviation. The above studies were repeated in another group of 20 
rats using the partially inactivated form of Duramycin. 
Compartmental model 
We modified a previously developed compartmental model for 
quantitative interpretation of the uptake kinetics of active and partially 
inactivated 9mTc-Duramycin in normal and infarct myocardium [17]. 
The model (Figure 1) consists a vascular region with volume V1 (ml) 
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representing the coronary circulation. For MI, the model allows 99mTc-
Duramycin to participate in specific binding, where B is the amount 
(nmol) of free binding sited that are readily accessible to 99mTc-
Duramycin at time t, and ks (ml nmol−1 min−1) is the association rate 
constant of 99mTc-Duramycin interaction with binding sites. For normal 
myocardial tissue, the model assumes that the binding sites are not 
accessible to 99mTc-Duramycin from the coronary circulation. 
 
Figure 1 Compartmental model for the disposition of 99mTc-Duramycin in ischemic 
cardiac tissue (a.) and viable tissue (b.). [C1](t) is the probe concentration in the MI 
vascular region at time t; C2(t) is the amount of bound probe at time t. B is the 
amount of free receptors or binding sites at time t that is readily accessible for probe 
within the MI blood region; ks is the probe-receptor association rate constant; F is the 
blood flow of the coronary circulation and [Cin](t) is the input probe concentration for 
the coronary circulation.  
Using mass balance and mass action, the temporal variations in 
the activities of free and bound 99mTc-Duramycin in V1 are described by 
Equations (1–2)  
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where [C1](t) is the probe concentration (µM) in the MI vascular space 
at time t (t = 0 is probe injection time); C2(t) is the amount (nmol) of 
probe sequestered in the MI region via specific binding at time t; F is 
the blood flow of the coronary circulation (~ 1 ml min−1 g−1); [Cin](t) is 
the input probe concentration for the coronary circulation, which was 
estimated from previously measured 99mTc-Duramycin plasma 
clearance profile as described below; and Bmax is the total amount 
(nmol) of readily accessible receptors or binding sites. The above 
equations are subject to the following initial (t = 0) conditions: [C1](t 
) = 0 µM, and C2(t) = 0 nmol. The total activated probe concentration 
at a given time t, Ctotal(t) in %ID g−1 of tissue, in the system is  
 
where ID (g) is the injected dose (~10 µg per 300 g rat); m (g) 
is the total mass of at-risk tissue (average 201 mg), and MW is the 
molecular weight of the radiopharmaceutical (3035 g mol −1). 
The model assumes that the partially inactivated form of 99mTc-
Duramycin differs from the active form only in its affinity for the 
binding sites. Thus, the active and partially inactivated forms have the 
same Bmax, V1 and [Cin](t), but different ks values. 
The governing differential equations for the disposition of 99mTc-
Duramycin in normal myocardium reduce to Equation (1) with Bmax set 
to zero. Thus, for normal myocardium, Equation (3) reduces to:  
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Statistical comparisons were carried out using t-test or paired t-
test, with P < 0.05 as the criterion for statistical significance. 
RESULTS 
Whole-body imaging 
Whole-body SPECT images are shown in Figure 2. The high focal 
uptake of radioactivity is clearly seen in the ischemic myocardium in 
the tomographic images, which is made more conspicuous because of 
a lack of significant hepatic background. This is accompanied with a 
low systemic background and rapid renal/urinary clearance. 
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Figure 2 Representative SPECT/CT images of 99mTc-Duramycin uptake in 
ischemically damaged cardiac tissue in vivo. The CT, SPECT and SPECT/CT fusion 
images are shown in the left, middle and right columns, respectively. Radioactivity 
uptake in the left ventricular free wall is highlighted with an arrow in the tomographic 
images.  
Spatial and Temporal uptake of 99mTc-Duramycin in the 
area-at-risk 
The uptake kinetics of 99mTc-Duramycin in the area-at-risk was 
characterized by measuring the level of radioactivity at different time 
points after injection and is summarized in Figure 3. Quantitative 
uptake data from dissected heart tissues of the infarct, and normal 
myocardium at 3, 10, 20, 60 and 180 min after tracer injection are 
presented. After injection the radioactivity uptake in the infarcted 
myocardium rapidly rose to 1.66 ± 1.18 (SD) %ID/g within 3 min, and 
approached a plateau by 10 min at 3.66 ± 0.76 %ID/g. The 
radioactivity uptake in the normal myocardium was low, reflecting the 
residual blood pool signal. According to the measurements using 
dissected heart tissues, at 60 min after injection, the average infarct-
to-normal ratio was ~29. The radiotracer was sequestered in the 
irreversibly damaged myocardium, which is consistent with the high 
binding affinity and specificity of Duramycin-PE interactions. Chemical 
modification of a single amino acid (D15) resulted in a marked 
reduction in probe uptake (Figure 3). 
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Figure 3 Kinetic analysis. Radioactivity uptake of the active and partially 
inactivated 99mTc-Duramycin, in terms of %ID/g, in ischemic and normal myocardium 
at 3, 10, 20, 60, and 180 min after intravenous injection. Values are mean ± SD. N = 
4 for active and partially inactivated 99mTc-Duramycin at each of the time points. Solid 
lines are model fits. * Uptake of 99mTc-Duramycin in area-at-risk is significantly 
different from that for the partially inactivated 99mTc-Duramycin at the same time point 
(P < 0.05). # Uptake of partially inactivated 99mTc-Duramycin in area-at-risk is 
significantly different from its uptake in viable tissue at the same time (P < 0.05)  
Kinetic analysis 
The model parameters are V1 (ml), the volume of the vascular 
region; Bmax (nmol) the total amount of specific receptors or binding 
sites accessible to 99mTc-Duramycin in MI tissue; and ks (ml nmol −1 
min−1), the probe-receptor association rate constant. Estimation of 
these parameters was carried out as follows. First, Cb(t), as %ID, was 
determined by fitting Equation (5) to previously measured 99mTc-
Duramycin plasma clearance profile as a fraction of injected dose.  
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where a, b and (100 − a − b) are the amplitudes of the three 
exponentials with rate constants α1 α2, and α3, respectively. The 
estimated values of the amplitudes a and b were 19.0 and 19.1 %ID, 
respectively. The estimated values of the rates constant α1, α2 and α3 
were 0.42, 0.02 and 0.42 min−1, respectively, and the estimated half-
life of the probe was 2.2 min. 
Knowing Cb(t), the input probe concentration for the coronary 
circulation, [Cin](t) (in µM), was determined using  
 
where Vin (ml) is the rat blood volume (~ 7% of total body 
weight). 
Knowing [Cin](t), V1 (ml) was estimated by solving Equation (1) 
with Bmax = 0, and fitting Equation (4) to active or partially 
inactivated 99mTc-Duramycin activity versus time uptake data in 
normal myocardium (Figure 1). The estimated values of V1 from the 
active or partially inactivated 99mTc-Duramycin uptake data were 
virtually the same (Table 1). Knowing V1, the remaining parameters 
namely, Bmax, and the association rate constant (ks) for the active 
(ksa ) and partially inactivated (ksi) 99mTc-Duramycin were then 
estimated by solving Equations (1–2) with ks set to ksa or ksi, and 
fitting the resulting solutions of Equation (5) simultaneously to the 
active and partially inactive 99mTc-Duramycin uptake data in MI (Figure 
3). The solid lines in Figure 3 demonstrate the ability of the model to 
fit the data. 
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Table 1 Estimated values and asymptotic confidence intervals of kinetic model 
parameters for 99mTc-Duramycin in area-at-risk 
ksa: binding rate constant for 99mTc-Duramycin. 
ksi: binding rate constant for the partially inactivated 99mTc-Duramycin. 
Table 1 shows the estimated values of the model parameters 
and measures of precision of these estimates, namely asymptotic 95% 
confidence intervals. 
DISCUSSION 
Significant findings from the current investigation include the 
follows: i) 99mTc-Duramycin has rapid uptake in the target tissue, 
presumably in a PE-dependent manner. Once bound, there is minimal 
washout over extended period of time. ii) The binding kinetics of 99mTc-
Duramycin is quantitatively analyzed, where these values allow an in-
depth understanding of the strength and limitations of this imaging 
agent. An added benefit is that the availability of quantitative kinetic 
data enables an assessment of incremental values and for guiding the 
development of future generation agents. The current findings are 
discussed in more details as follows. 
Cognate interactions between the probe and binding target are 
dependent on the accessibility of these targets to probe from the 
vascular region. Smaller probes tend to have a greater tissue 
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permeability, which leads to a more efficient target access. To date, a 
phospholipid-binding agent other than 99mTc-Duramycin with 
established quantitative kinetic data is 99mTc-C2A-GST. Comparatively, 
probe’s tissue permeability was a limiting factor for 99mTc-C2A-GST, 
but not for 99mTc-Duramycin, in part due to its much lower molecular 
weight. 
Using kinetic analysis, we were able to estimate the binding rate 
constant for 99mTc-Duramycin in the target tissue. This value reflects 
the binding affinity of the agent in the actual tissue settings. The 
availability of the in vivo binding rate constant enables comparative 
studies that are free from extrapolations based on binding constants 
obtained from in vitro binding assays. According to the current study, 
the binding rate constant (ks) for 99mTc-Duramycin is comparable than 
that of 99mTc-C2A-GST (Table 2) [13]. Quantitative analysis indicates 
that covalent modification of D15, which forms a portion of Duramycin 
binding pocket, resulted in a substantial decrease in binding rate 
constant. This is indicative that the uptake of 99mTc-Duramycin is 
indeed PE dependent. 
 
Table 2 Comparison of values of model parameters descriptive of the uptake of 
99mTc-Duramycin and 99mTc-C2A-GST in area-at-risk 
V1 and Bmax are normalized to mass of at-risk tissue. ksa is binding rate constant for 
99mTc-Duramycin. 
In terms of total binding capacity (Bmax), this is a parameter that 
is intrinsic to the target tissue, and is a measure of the available 
binding sites for a given probe. By comparing the kinetics between 
99mTc-Duramycin and 99mTc-C2A-GST, two membrane-binding agents 
that differ from structural properties to binding targets, it provides a 
unique opportunity to look at the total binding capacity from two 
independent angles. According to the kinetic analysis results, the Bmax 
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(nmol/g) for 99mTc-Duramycin, which is the density of available PE, is 
about 3-fold greater than that of 99mTc-C2A-GST (Table 2), which is 
the density of available PS [13]. This outcome is consistent with the 
published values of PE/PS ratio from cellular membranes [14]. It is 
indicative that the molecular targets, PE and PS, are constituents of a 
single pool of membrane phospholipids exposed in dead and dying 
cells. A significant point of the current study, therefore, is that the 
underlying pathophysiology is a constant beyond the variability of 
different imaging agents or their targets. 
The ~3-fold difference in the number of available binding sites 
for 99mTc-Duramycin as compared to 99mTc-C2A-GST resulted in only 
~50% increase in the uptake of 99mTc-Duramycin in MI at steady state 
as compared to 99mTc-C2A-GST [13]. This result is in part due to the 
faster blood clearance rate of 99mTc-C2A-GST as compared to 99mTc-
C2A-GST (Table 2). This stresses the importance of the above kinetic 
modeling approach for the quantitative interpretation of 99mTc-
Duramycin kinetic data since the 3-fold difference in the number of 
available binding sites cannot be predicted directly from the kinetic 
data without accounting for the contributions of the other factors that 
determine the uptake kinetics of 99mTc-Duramycin in MI, including 
blood clearance rate, probe tissue permeability, and probe-target 
binding rate constant. 
In terms of potential impact on patient care, current clinical 
radiotracers are valuable in providing perfusion, functional and 
metabolic information on target tissues, such as the heart; however, 
there lacks a positive imaging agent for detecting active cell death in 
degenerative diseases. A targeted radiotracer that binds externalized 
phospholipids as a surrogate marker for cell death will aid the early 
detection of tissue injury and the monitoring of the efficacy of 
therapeutic interventions. 
Overall, in a quantitative approach, we have characterized the in 
vivo behaviors of 99mTc-Duramycin in the target tissue. The relatively 
high target-to-background ratio is due to a combination of the 
following factors: enhanced tissue permeability, site-directed 
radiolabeling, prompt blood clearance, and a greater target density. 
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